ACH
MRSN

ArrowMark Colorado Holdings’s Mersana Therapeutics MRSN Stock Holding History

ArrowMark Colorado Holdings’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,600
Closed -$2.4M – 350
2020
Q4 		$2.4M Hold
3,600
– – 0.02% 257
2020
Q3 		$1.68M Hold
3,600
– – 0.02% 268
2020
Q2 		$2.11M Buy
+3,600
New +$1.23M 0.02% 230
2019
Q4 		– Sell
-16,541
Closed -$653K – 320
2019
Q3 		$653K Sell
16,541
-82,036
-83% -$5.96M 0.01% 269
2019
Q2 		$9.98M Sell
98,577
-30,063
-23% -$3.54M 0.1% 171
2019
Q1 		$16.9M Buy
128,640
+47,540
+59% +$5.98M 0.16% 121
2018
Q4 		$8.27M Buy
81,100
+7,487
+10% +$1.18M 0.09% 192
2018
Q3 		$18.4M Buy
73,613
+23,574
+47% +$7.9M 0.15% 130
2018
Q2 		$22.3M Buy
50,039
+12,743
+34% +$5.59M 0.21% 111
2018
Q1 		$14.7M Buy
37,296
+1,305
+4% +$515K 0.15% 141
2017
Q4 		$14.8M Buy
35,991
+16,883
+88% +$7.36M 0.15% 137
2017
Q3 		$8.26M Buy
19,108
+5,108
+36% +$2.01M 0.09% 184
2017
Q2 		$4.89M Buy
+14,000
New +$4.84M 0.06% 208

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

ArrowMark Colorado Holdings's MRSN Position: Q1 2021 in Review

ArrowMark Colorado Holdings sold out of Mersana Therapeutics (MRSN) in Q1 2021, closing a stake of 3,600 shares — an estimated $2.4M sold.

ArrowMark Colorado Holdings first reported a position in MRSN in Q2 2017 and held it in 13 quarters. The position peaked at $22.3M in Q2 2018. 132 funds tracked by Wall St. Rank hold MRSN as of Q1 2021.

  • ArrowMark Colorado Holdings reported no remaining Mersana Therapeutics position as of Q1 2021 after selling out during the quarter.
  • ArrowMark Colorado Holdings sold 3,600 Mersana Therapeutics shares in Q1 2021, an estimated $2.4M.
  • ArrowMark Colorado Holdings first reported a position in Mersana Therapeutics in Q2 2017 and held it in 13 quarters.
  • ArrowMark Colorado Holdings's Mersana Therapeutics position peaked at $22.3M in Q2 2018.
  • 132 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2021.

Based on ArrowMark Colorado Holdings's 13F filing for Q1 2021, filed 17 May 2021.